Jun 2026 (Q2 FY26) — Aug 12, 2026
Aquestive Q2 FY26 — Anaphylm Resubmission On Track, Strong Clinical Data
Read the full callAquestive (AQST) earnings
- Jun 2026
- Jun 2026 (Q2 FY26)
- Dec 2025
Aquestive earnings: last reported Wed, 12 Aug 2026, for the quarter ended Jun 2026.
Reported
The figures, each with its period
Each figure keeps its basis and period; nothing is filled in.
| Metric | Value | Change | Basis | Period | Note |
|---|---|---|---|---|---|
| Revenue | 13.8 | +38.1% YoY | Quarterly, as filed | Quarter to Jun 2026 | Revenue from operations as filed. |
| Operating margin | -59.5 | +54.1 pts YoY | Operating profit / revenue | Quarter to Jun 2026 | For the quarter; a change is in percentage points. |
| Net profit | -22.9 | Quarterly, as filed | Quarter to Jun 2026 | Profit after tax as filed. The year-earlier figure was zero or a loss, so no percentage is shown. |
Price
$4.06 −11.93% · −$0.55
Performance −41.0% 1Y
1Y: $6.88 on 14 Oct 2025 → $4.06. High $7.49 (20 Oct 2025), low $2.95 (30 Jan 2026).
- Previous close
- $4.61
- 52-week range
- $2.95 – $7.49
- One year
- −44.69%
Overview
- Symbol
- AQST
- Sector
- Health Care
- Exchange
- US
- Currency
- USD
Call summaries
Every analysed call
Aquestive earnings calls (AQST)
Financials
What the filings say
Net profit, year on year: −69% (quarter to jun 2026 against jun 2025).
| Line item | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 14 | 12 | 9 | 10 | 13 | 13 | 14 | 14 |
| Expenses | 22 | 25 | 28 | 21 | 24 | 42 | 19 | 22 |
| Operating profit | -8 | -14 | -19 | -11 | -11 | -29 | -4 | -8 |
| Operating margin | −61.2% | −114.4% | −222.1% | −113.7% | −89.6% | −221.6% | −29.1% | −59.5% |
| Interest | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 |
| Profit before tax | -12 | -17 | -23 | -14 | -15 | -32 | -8 | -23 |
| Tax rate | 0.0% | 0.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net profit | -12 | -17 | -23 | -14 | -15 | -32 | -8 | -23 |
| EPS ($ per share) | -0.13 | — | -0.24 | -0.14 | -0.14 | — | -0.07 | -0.18 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Equity capital | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Reserves | -61 | -130 | -186 | -257 | -311 | -319 | -363 | -447 |
| Total liabilities | 77 | 85 | 111 | 144 | 176 | 164 | 162 | 194 |
| Fixed assets | 12 | 10 | 7 | 5 | 4 | 4 | 4 | 4 |
| Total assets | 87 | 78 | 63 | 62 | 57 | 57 | 101 | 160 |
| Line item | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | -13 | -60 | -45 | -33 | -10 | -6 | -36 | -52 |
| Cash from investing | -2 | -1 | -1 | -1 | -3 | -1 | -0 | -1 |
| Cash from financing | 58 | 50 | 28 | 30 | 12 | 4 | 84 | 103 |
| Net cash flow | — | — | -18 | -4 | -1 | -3 | 48 | 50 |
| Capital expenditure | -2 | -1 | -1 | -1 | -1 | -1 | -0 | -1 |
| Free cash flow | -15 | -61 | -46 | -34 | -11 | -7 | -36 | -53 |
Insider filings
42 filings between Nov 10, 2025 and Sep 15, 2026.
Open market
decisions to buy or sellPurchases
None
No insider bought shares.
Sales
$2.29M
15 sales by 8 insiders
53% filed under a 10b5-1 plan — scheduled in advance, not decided on the day
Compensation
not trading decisions- 12
- Award — granted as compensation
- 2
- Option exercise — converted options into shares
- 10
- Tax withheld — shares kept back by the company to cover tax
Also filed: 3 option exercises.
Who traded
open market only| Insider | Bought | Sold | Last filing |
|---|---|---|---|
| Barber Daniel | — | $1.22M | Sep 15, 2026 |
| TOTH A ERNEST JR | — | $243.1K | Mar 10, 2026 |
| Jung Cassie | — | $191.1K | Mar 10, 2026 |
| BRAENDER LORI J | — | $167.3K | Mar 10, 2026 |
| Krop Julie | — | $125.4K | Jun 23, 2026 |
| Boyd Peter E. | — | $124.4K | Mar 10, 2026 |
| Korczynski Sherry | — | $111.4K | Sep 9, 2026 |
| Cioffi Melina | — | $105.6K | Mar 10, 2026 |
Latest filings (50)
| Date | Insider | What | Shares | Value |
|---|---|---|---|---|
| Sep 15, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 25,000 | $120.5K |
| Sep 9, 2026 | Korczynski Sherry Chief Commercial Officer | Sale 10b5-1 plan | 8,750 | $45.7K |
| Sep 9, 2026 | Korczynski Sherry Chief Commercial Officer | Option exercise 10b5-1 plan | 8,750 | $23.2K |
| Sep 9, 2026 | Boyd Peter E. Chief People Officer | Option exercised | 2,293 | $2.2K |
| Sep 8, 2026 | Barber Daniel President and CEO | Option exercised | 91,743 | $88.1K |
| Sep 3, 2026 | Jung Cassie Chief Operating Officer | Option exercised | 4,587 | $4.4K |
| Aug 17, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 25,000 | $107.2K |
| Aug 14, 2026 | Korczynski Sherry Chief Commercial Officer | Tax withheld | 2,714 | $11.5K |
| Jul 16, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 20,369 | $81.5K |
| Jul 15, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 4,631 | $18.7K |
| Jun 23, 2026 | Krop Julie Director | Sale 10b5-1 plan | 25,000 | $125.4K |
| Jun 23, 2026 | Krop Julie Director | Option exercise 10b5-1 plan | 25,000 | $17.8K |
| Jun 15, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 25,000 | $104.0K |
| Jun 8, 2026 | Korczynski Sherry Chief Commercial Officer | Tax withheld | 2,714 | $0 |
| May 18, 2026 | Zalewski Thomas A. Chief Legal Officer | Award | 100,000 | $0 |
| May 15, 2026 | Barber Daniel President and CEO | Sale 10b5-1 plan | 8,257 | $35.4K |
| May 15, 2026 | Cioffi Melina SVP, Regulatory Affairs | Tax withheld | 1,667 | $7.0K |
| May 7, 2026 | BRAENDER LORI J Corporate Secretary | Tax withheld | 135,690 | $574.0K |
| May 5, 2026 | Boyd Peter E. Chief People Officer | Tax withheld | 56,778 | $237.3K |
| May 5, 2026 | Barber Daniel President and CEO | Tax withheld | 335,922 | $1.40M |
| May 5, 2026 | TOTH A ERNEST JR Chief Financial Officer | Tax withheld | 92,652 | $387.3K |
| May 5, 2026 | Jung Cassie Chief Operating Officer | Tax withheld | 72,734 | $304.0K |
| May 5, 2026 | BRAENDER LORI J Corporate Secretary | Tax withheld | 76,147 | $318.3K |
| Mar 10, 2026 | Cioffi Melina SVP, Regulatory Affairs | Sale | 25,311 | $105.6K |
| Mar 10, 2026 | Jung Cassie Chief Operating Officer | Sale | 45,791 | $191.1K |
| Mar 10, 2026 | Korczynski Sherry Chief Commercial Officer | Sale | 15,741 | $65.7K |
| Mar 10, 2026 | TOTH A ERNEST JR Chief Financial Officer | Sale | 58,254 | $243.1K |
| Mar 10, 2026 | BRAENDER LORI J Chief Legal Officer | Sale | 40,102 | $167.3K |
| Mar 10, 2026 | Barber Daniel President and CEO | Sale | 180,677 | $754.0K |
| Mar 10, 2026 | Boyd Peter E. Chief People Officer | Sale | 29,814 | $124.4K |
| Mar 9, 2026 | Jung Cassie Chief Operating Officer | Award | 80,000 | $0 |
| Mar 9, 2026 | Barber Daniel President and CEO | Award | 262,000 | $0 |
| Mar 9, 2026 | Davis Matthew W. Chief Development Officer | Award | 50,000 | $0 |
| Mar 9, 2026 | Boyd Peter E. Chief People Officer | Award | 80,000 | $0 |
| Mar 9, 2026 | Greenhawt Matthew J. Chief Medical Officer | Award | 75,000 | $0 |
| Mar 9, 2026 | Korczynski Sherry Chief Commercial Officer | Award | 75,000 | $0 |
| Mar 9, 2026 | Cioffi Melina SVP, Regulatory Affairs | Award | 100,000 | $0 |
| Mar 9, 2026 | TOTH A ERNEST JR Chief Financial Officer | Award | 95,000 | $0 |
| Mar 9, 2026 | BRAENDER LORI J Chief Legal Officer | Award | 80,000 | $0 |
| Dec 4, 2025 | Boyd Peter E. Chief People Officer | Award | 20,000 | $0 |
| Dec 2, 2025 | Cioffi Melina SVP, Regulatory Affairs | Tax withheld | 2,083 | $12.4K |
| Nov 10, 2025 | Davis Matthew W. Chief Development Officer | Award | 50,000 | $0 |
| Oct 15, 2025 | Jung Cassie Chief Operating Officer | Option exercise 10b5-1 plan | 25,000 | $77.6K |
| Oct 15, 2025 | Jung Cassie Chief Operating Officer | Sale 10b5-1 plan | 67,575 | $473.7K |
| Oct 15, 2025 | Kraus Carl N Chief Medical Officer | Sale 10b5-1 plan | 20,272 | $141.9K |
| Oct 15, 2025 | Boyd Peter E. See Remarks | Sale 10b5-1 plan | 10,000 | $70.0K |
| Sep 26, 2025 | Barber Daniel President and CEO | Sale 10b5-1 plan | 91,343 | $551.2K |
| Sep 26, 2025 | Boyd Peter E. See Remarks | Sale 10b5-1 plan | 10,000 | $63.0K |
| Sep 19, 2025 | Barber Daniel President and CEO | Sale 10b5-1 plan | 400 | $2.4K |
| Sep 5, 2025 | Boyd Peter E. See Remarks | Sale 10b5-1 plan | 15,000 | $79.5K |
Source: SEC Form 4 filings. Form 4 reports transactions, not the cap table — absence of filings says nothing about how much an insider owns, and a quiet window is not a signal.
Your own record
Start an Inve Case for Aquestive Therapeutics, Inc.
Free account. Everything above stays public.
Write why you follow Aquestive Therapeutics, Inc. and the condition you want checked. Inve compares your numeric conditions with available results and management guidance; your own conditions remain yours to review.
Keep reading